Intas launches Mabtas, a biosimilar version of Rituximab - PharmaBiz.com pharmabiz.com Intas Pharmaceuticals Ltd. has launched Mabtas, a biosimilar version of Rituximab competent in treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells like Chronic Lymphocytic Leukaemia (CLL) and ... |
